Return to Home Incidence > Table

Incidence Rates Table

Data Options

Incidence Rate Report by State

Melanoma of the Skin (Late Stage^), 2016-2020

All Races (includes Hispanic), Both Sexes, All Ages

Sorted by CI*Rank
State
 sort alphabetically by name ascending
Age-Adjusted Incidence Rate
cases per 100,000
(95% Confidence Interval)
 sort by rate descending
CI*Rank⋔
(95% Confidence Interval)
 sort by CI rank ascending
Average Annual Count
 sort by count descending
Percent of Cases with Late Stage
 sort by percent late descending
US (SEER+NPCR) 1 3.1 (3.1, 3.1) N/A 11,643 13.9
District of Columbia 6 1.5 (1.1, 2.0) 49 (48, 49) 10 15.1
Alaska 6 2.1 (1.6, 2.6) 48 (37, 49) 16 15.1
Louisiana 3 2.5 (2.3, 2.7) 47 (39, 48) 133 14.4
New York 3 2.5 (2.4, 2.6) 46 (41, 48) 601 14.2
Maryland 6 2.5 (2.3, 2.7) 45 (39, 48) 177 10.2
Texas 3 2.5 (2.4, 2.6) 44 (41, 48) 724 17.8
New Mexico 3 2.5 (2.3, 2.8) 43 (34, 48) 66 15.1
Hawaii 3 2.6 (2.2, 2.9) 42 (30, 48) 47 10.6
New Jersey 3 2.7 (2.5, 2.8) 41 (37, 47) 296 12.9
Oregon 6 2.9 (2.6, 3.1) 40 (26, 44) 144 11.6
Connecticut 3 2.9 (2.6, 3.1) 39 (25, 45) 129 14.9
California 3 2.9 (2.8, 2.9) 38 (32, 41) 1,258 12.8
Arizona 6 2.9 (2.7, 3.1) 37 (28, 42) 252 9.9
Georgia 3 2.9 (2.8, 3.0) 36 (28, 42) 330 11.5
South Carolina 6 3.0 (2.8, 3.2) 35 (23, 41) 186 13.1
Virginia 6 3.0 (2.8, 3.1) 34 (26, 41) 290 14.0
Washington 5 3.1 (2.9, 3.3) 33 (21, 39) 265 12.0
Alabama 6 3.1 (2.9, 3.3) 32 (19, 40) 182 14.2
North Dakota 6 3.1 (2.6, 3.7) 31 (5, 47) 26 13.5
North Carolina 6 3.1 (3.0, 3.3) 30 (21, 37) 382 12.1
Illinois 3 3.1 (3.0, 3.3) 29 (21, 36) 468 14.1
Kansas 6 3.2 (2.9, 3.4) 28 (14, 40) 104 11.6
Mississippi 6 3.2 (2.9, 3.5) 27 (13, 40) 108 16.9
Oklahoma 6 3.2 (3.0, 3.5) 26 (14, 38) 144 15.1
Massachusetts 3 3.2 (3.1, 3.4) 25 (15, 35) 275 16.3
Arkansas 6 3.3 (3.0, 3.6) 24 (10, 38) 118 14.0
Missouri 6 3.3 (3.1, 3.5) 23 (14, 34) 236 17.5
Minnesota 6 3.3 (3.1, 3.6) 22 (12, 33) 215 9.3
Maine 6 3.4 (3.0, 3.8) 21 (6, 40) 64 12.8
Pennsylvania 6 3.4 (3.3, 3.5) 20 (13, 27) 563 16.2
South Dakota 6 3.5 (3.0, 4.1) 19 (2, 41) 35 12.6
Tennessee 6 3.5 (3.3, 3.7) 18 (8, 26) 282 17.4
Rhode Island 6 3.5 (3.1, 4.0) 17 (2, 38) 47 16.4
Michigan 6 3.5 (3.4, 3.7) 16 (9, 24) 428 17.6
Florida 6 3.6 (3.5, 3.7) 15 (9, 21) 1,048 13.9
Montana 6 3.6 (3.1, 4.1) 14 (2, 37) 48 12.9
Wisconsin 6 3.6 (3.4, 3.8) 13 (6, 23) 256 15.3
Colorado 6 3.7 (3.4, 3.9) 12 (5, 22) 228 17.2
Idaho 3 3.7 (3.3, 4.1) 11 (2, 29) 74 12.6
Wyoming 6 3.8 (3.2, 4.6) 10 (1, 39) 26 16.0
West Virginia 6 3.9 (3.5, 4.2) 9 (1, 23) 93 17.6
Delaware 6 3.9 (3.4, 4.5) 8 (1, 29) 48 13.8
Ohio 6 3.9 (3.8, 4.1) 7 (2, 12) 556 15.6
Kentucky 3 4.0 (3.7, 4.2) 6 (2, 16) 206 14.3
Nebraska 6 4.0 (3.6, 4.4) 5 (1, 21) 85 14.2
Iowa 3 4.0 (3.7, 4.3) 4 (1, 16) 151 13.6
Vermont 6 4.1 (3.5, 4.8) 3 (1, 30) 32 10.7
New Hampshire 6 4.3 (3.8, 4.8) 2 (1, 14) 73 13.2
Utah 3 4.5 (4.2, 4.9) 1 (1, 7) 128 11.1
Indiana 6
data not available
N/A
data not available
data not available
Nevada 6
data not available
N/A
data not available
data not available
Puerto Rico 6 0.6 (0.5, 0.7) N/A 24 17.9
Notes:
Created by statecancerprofiles.cancer.gov on 07/18/2024 3:18 am.

State Cancer Registries may provide more current or more local data.
Trend
Rising when 95% confidence interval of average annual percent change is above 0.
Stable when 95% confidence interval of average annual percent change includes 0.
Falling when 95% confidence interval of average annual percent change is below 0.

† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.

Rates are computed using cancers classified as malignant based on ICD-O-3. For more information see malignant.html.

^ Late Stage is defined as cases determined to be regional or distant. Due to changes in stage coding, Combined Summary Stage (2004+) is used for data from Surveillance, Epidemiology, and End Results (SEER) databases and Merged Summary Stage is used for data from National Program of Cancer Registries databases. Due to the increased complexity with staging, other staging variables maybe used if necessary.
⋔ Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. More information about methodology can be found on the CI*Rank website.

Data not available for this combination of data selections.

1 Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.
3 Source: SEER November 2022 submission. State Cancer Registry also receives funding from CDC's National Program of Cancer Registries.
5 Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.
6 Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2022 submission).
Data not available for this combination of geography, cancer site, age, and race/ethnicity.

Data for the United States does not include data from Nevada.
Data for the United States does not include Puerto Rico.
CI*Rank data for Puerto Rico is not available.

Return to Top